Presentation AHA 2024 Phase 2 Trial of Zerlasiran: Multiple doses of an siRNA Targeting Lipoprotein(a) over 60 weeks Presenter: Steven E. Nissen November 18, 2024
Presentation AHA 2023 Lepodisiran: An Extended-Duration siRNA Targeting Lipoprotein(a) Presenter: Steven E. Nissen November 11, 2023
Presentation ACC 2022 A Single Ascending Dose Study of an siRNA Targeting Lipoprotein(a) Presenter: Steven E. Nissen April 04, 2022
Presentation AHA 2018 Safety and Efficacy of AKCEA-APO(a)-LRx to Lower Lipoprotein(a) Levels in Patients With Established Cardiovascular Disease: A Phase 2 Dose-Ranging Trial Presenter: Sotirios Tsimikas November 11, 2018
Presentation EAS 2018 Lipoprotein(a), PCSK9 Inhibition and Cardiovascular Risk: Insights from the FOURIER Trial Presenter: Michelle L. O’Donoghue May 07, 2018
Presentation EAS 2018 LPA variants, risk of coronary disease, and estimated clinical benefit of lipoprotein(a) lowering therapies: a Mendelian randomization analysis Presenter: Brian A. Ference May 07, 2018
Presentation ACC 2017 Results of the CARAT Study: Effect of Serial Infusions of CER-001, a Pre-Beta High-Density Lipoprotein Mimetic on Coronary Atherosclerosis Presenter: Stephen J Nicholls March 20, 2017